Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas

Leukemia

Volumn 14, Issue 9, 2000, Pages 1533-1559

  Drexler, H G ^a   Gignac, S M ^a,b   Von Wasielewski, R ^b   Werner, M ^c   Dirks, W G ^a  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

ALCL; ALK; Cell lines; Hodgkin; NHL; NPM

Indexed keywords

DNA; MONOCLONAL ANTIBODY; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE; RNA; TYROSINE KINASE RECEPTOR;

ADULT; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER SURVIVAL; CARCINOGENESIS; CHILD; CHILDHOOD CANCER; CHROMOSOME 2P; CHROMOSOME 5Q; CHROMOSOME BREAKAGE; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 5; FUSION GENE; GENE REARRANGEMENT; GENETIC LINKAGE; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NONHODGKIN LYMPHOMA; NULL CELL; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SKIN LYMPHOMA; T CELL LYMPHOMA;

EID: 0033824668     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401878     Document Type: Review

References (303)

1. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells
2. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines
3. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells
4. Cytogenetic studies of childhood non-Hodgkin's lymphomas
5. Chromosome 5q35 breakpoint in malignant histiocytosis
6. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lympha-denopathy
7. Updated Kiel classification for lymphomas
8. Histopathology and immunohistochemistry of peripheral T-cell lymphomas: A proposal for their classification
9. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
10. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
11. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
12. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry
13. Large-cell anaplastic lymphoma-specific translocation (t[2;5][p23;q35]) in Hodgkin's disease: Indication of a common pathogenesis
14. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1
15. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
16. ALK expression defines a distinct group of T/null lymphomas ('ALK lymphomas') with a wide morphological spectrum
17. ALK+ lymphoma: Clinico-pathological findings and outcome
18. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues
19. Hodgkin's disease: Classification and biology
20. Anaplastic large cell lymphoma (ALCL) and Hodgkin's disease (HD)
21. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)
22. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis
23. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma
24. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
25. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation
26. Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood
27. Childhood non-Hodgkin lymphomas in the United Kingdom: Findings from the UK Children's Cancer Study Group
28. NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 1: Classification and allocation to strategic therapy groups. BFM study group
29. Ki-1 (CD30) anaplastic large-cell lymphoma in children
30. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid
31. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Neoplasm: A comparison with the Working Formulation
32. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
33. Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome
34. Pediatric lymphomas: Recent advances and commentary on Ki-1 positive anaplastic large-cell lymphomas of childhood
35. Non-Hodgkin's lymphoma in childhood
36. Peripheral T-cell lymphoma in children and adolescents: Role of bone marrow transplantation
37. Primary Ki-1-positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity
38. CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy
39. Epstein-Barr virus and CD30+ malignant lymphomas
40. CD30 in normal and neoplastic cells
41. Anaplastic large cell lymphoma: Update of findings
42. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation
43. Childhood anaplastic large cell lymphoma Ki-1/CD30: Clinicopathologic features of 19 cases
44. Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease
45. Primary Ki-1 anaplastic large-cell lymphoma in adults: Clinical characteristics and therapeutic outcome
46. Prognostic significance of anaplastic large cell lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
47. Molecular characterization of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease
48. Ki-1+ anaplastic large cell lymphoma (ALCL): Correlation of clinical features with p80(NPM/ALK) expression and histology
49. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis
50. Ki-1 positive large cell lymphoma: A morphologic and immunologic study of 19 cases
51. Ki-1 positive large cell lymphoma: A clinicopathologic study of 41 cases
52. Anaplastic large cell lymphoma: A distinct molecular pathologic entitity: A reappraisal with special reference to p80(NPM/ALK) expression
53. Expression of carbohydrate antigens, p80(NPM/ALK), cytotoxic cell-associated antigens, and Epstein-Barr virus gene products in anaplastic large cell lymphomas
54. Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types
55. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction
56. Anaplastic large cell lymphomas expressing the novel chimeric protein p80(NPM/ALK): A distinct entity
57. Low frequency association of the t(2;5)(p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients
58. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions
59. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements
60. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin
61. CD30-positive anaplastic large cell lymphoma in childhood: Expression of p80(npm/alk) and absence of Epstein-Barr virus
62. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, p-80 staining
63. Detection of t(2;5) in anaplastic large cell lymphoma. Comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue
64. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease
65. Diffuse large cell lymphomas of B and T cell type
66. Ki-1 anaplastic large cell lymphoma: Is it a discrete entity
67. Anaplastic large cell lymphoma and its morphological variants
68. Hodgkin's disease and CD30-positive anaplastic large cell lymphomas - a continuous spectrum of malignant disorders
69. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma
70. + with a high content of reactive histiocytes)
71. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type
72. CD30+ anaplastic large-cell lymphoma, null type, with signet-ring appearance
73. Sarcomatoid variant of anaplastic large cell Ki-1 lymphoma
74. Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma
75. ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease
76. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma
77. Malignant histiocytosis in childhood: A distinctive CD30-positive clinicopathological entity associated with a chromosomal translocation involving 5q35
78. Histiocytes and histiocytosis
79. Malignant histiocytosis. Histologic, cytochemical, chromosomal, and molecular data with a nosologic discussion
80. Malignant histiocytosis: A reassessment of cases formerly classified as histiocytic neoplasm and review of the literature
81. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis
82. Malignant histiocytosis. A reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies
83. Malignant lymphomas of true histiocytic origin. A clinical, histological, immunophenotypic and genotypic study
84. Regressing atypical histiocytosis: A review and critical reappraisal
85. The nature of Hodgkin and Reed-Sternberg cells, their association with EBV, and their relationship to anaplastic large-cell lymphoma
86. Anaplastic large cell lymphoma, CD30/Ki-1 positive, expressing the CD15/LeuM1 antigen
87. The distinction of Hodgkin's disease from anaplastic large cell lymphoma
88. The relationship between Hodgkin's disease and non-Hodgkin's lymphoma
89. Differential diagnosis between Hodgkin's disease and non-Hodgkin's lymphoma
90. Nodular lymphocyte predominant Hodgkin's disease and anaplastic large-cell (CD30+) lymphoma: Distinct entities or nonspecific patterns?
91. Hodgkin's lymphomas: Classification, diagnosis, and grading
92. +) anaplastic large cell lymphomas. Morphologic, immunohistologic and clinical characteristics
93. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: A proposal for classification and guidelines for management and treatment
94. + (anaplastic) large cell lymphoma: Maturation of a clinicopathologic entity with prospects of effective therapy
95. Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases
96. Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma
97. Clinicopathologic study of large cell anaplastic lymphoma (Ki-1-positive large cell lymphoma) among the Japanese
98. Long-term prognostic importance of primary Ki-1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large-cell lymphoma
99. Clinical features and treatment outcome for children with CD30-positive large cell non-Hodgkin's lymphoma
100. CD30 (Ki-1)-positive malignant lymphomas: Clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease
101. Anaplastic large-cell lymphoma: Clinical and prognostic evaluation of 90 adult patients
102. Clinical features of CD30 (Ki-1) positive anaplastic large-cell lymphoma (ALCL). Review of the literature
103. Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable diagnosis
104. CD30+ anaplastic large cell lymphomas
105. CD30 (Ki-1)-positive anaplastic large-cell lymphoma in 13 patients with and 27 patients without human immunodeficiency virus infection: The first comparative clinicopathologic study from a single institution that also 80 patients with other immunodeficiency virus-related systemic lymphomas
106. Anaplastic large cell (CD30/Ki-1+) lymphoma in HIV+ patients: Clinical and pathological findings in a group of ten patients
107. Cytogenetic evolution patterns in non-Hodgkin's lymphoma
108. Recurrent chromosomal translocations and fusion genes in leukemia-lymphoma cell lines
109. Malignant histiocytosis: A specific t(2;5)(p23;q35) translocation? Review of the literature
110. Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis
111. Recurring chromosome translocations in B-cell malignant lymphoma
112. Chromosomal t(2;5) and hematological malignancies
113. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis
114. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35
115. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene
116. The t(2;5)(p23;q35): A recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma
117. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma')
118. Morphology in Ki-1 (CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35)
119. t(2;5)(p23;q35) - A specific chromosome abnormality in large cell anaplastic (Ki-1) lymphoma
120. Karyotype and prognosis in non-Hodgkin's lymphoma
121. Immunohistochemical, molecular, and cytogenetic analysis of a consecutive series of 20 peripheral T-cell lymphomas of uncertain lineage, including twelve Ki-1 positive lymphomas
122. Cytogenetic analysis of 434 consecutively ascertained specimens on non-Hodgkin's lymphoma: Correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment
123. Cytogenetic findings in peripheral T-cell lymphomas as a basis for distinguishing low-grade and high-grade lymphomas
124. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35)
125. Predictive biological and clinical markers in ALK-positive large cell lymphoma in children
126. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma
127. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease
128. Chromosomal abnormalities in Hodgkin's disease suggest possible origin from a lymphocyte
129. Clonal cytogenetic abnormalities in Hodgkin's disease
130. Cytogenetic studies in untreated Hodgkin's disease
131. Chromosomal abnormalities in Hodgkin's disease
132. Recurrent chromosome abnormalities in peripheral T-cell lymphomas
133. Classification of peripheral T-cell lymphomas. Cytogenetic findings support the updated Kiel classification
134. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)
135. Biological characteristics of chronic eosinophilic leukemia cells with a t(2;5)(p23;q35) translocation
136. t(1;2)(p21;p23) and t(2;3)(p23q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma
137. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma
138. Deletion(2)(p23) abnormality in a case of secondary acute myeloid leukemia
139. del(2)(p23): A new recurrent abnormality in acute myeloid leukemia
140. del(2)(p23): A consistent recurrent abnormality in acute myelogenous leukemia
141. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma
142. + anaplastic large cell lymphoma
143. t(2;3)(p23;q26) in a patient with AML M2
144. A third case of apparent t(2;4)(p23;q25) represents ins(2;4) with deletion of 2p
145. Translocation (2;4)(p23;q25): An additional case of a new recurrent anomaly in acute myeloid leukemia
146. Novel translocation (2;4) with consistent involvement of 2p23 in acute nonlymphocytic leukemia (M2)
147. A novel variant translocation t(2;13)(p23;q34) in Ki-1 large cell anaplastic lymphoma
148. Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21
149. Leukemic presentation in a child of an anaplastic large cell lymphoma (ALCL) with a natural killer cell phenotype and a novel translocation involving the ALK gene
150. Diffuse large cell B-cell type lymphoma with a novel translocation (2;22)(p23;q11.2)
151. Translocation (1;5)(q32;q35) in CD30+ anaplastic large cell non-Hodgkin lymphoma of childhood
152. Clinicopathologic manifestations and breakpoints of the t(3;5) in patients with acute non-lymphocytic leukemia
153. Non-Hodgkin's lymphomas and myeloid disorders: Deletions associated with t(2;5) and t(3;5) detected by FISH
154. The (3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1
155. Translocation (3;5)(q21;q34) in erythroleukemia: A molecular and in situ hybridization study
156. Cytogenetic study of malignant histiocytosis transplanted into nude mice: Presence of translocation between chromosomes 5 and 6 and a unique marker (13q+)
157. DEL cell line: A 'malignant histiocytosis' CD30+ t(5;6)(q35;p21) cell line
158. A non-classical translocation involving 17q12 (retinoic acid receptorα) in acute promyelocytic leukemia (APML) with atypical features
159. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion
160. Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia
161. A new t(2;5) translocation in a null cell type CD30 positive anaplastic large cell lymphoma case
162. The (2;5)(p;23;q35) translocation in cell lines derived from malignant lymphomas: Absence of t(2;5) in Hodgkin-analogous cell lines
163. FLT4 receptor tyrosine kinase gene mapping to chromosome band 5q35 in relation to the t(2;5), t(5;6), and t(3;5) translocations
164. Localization of two tyrosine kinase receptor genes with respect to the 5q35 chromosomal breakpoint of Ki-1 lymphoma cell lines
165. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia
166. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
167. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
168. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
169. Signal transduction by receptors with tyrosine kinase activity
170. t(2;5) translocations in anaplastic large cell lymphomas and Hodgkin's disease
171. Major nucleolar proteins shuttle between nucleus and cytoplasm
172. Isolation and characterization of the human nucleophosmin/B23 (NPM) gene: Identification of the YY1 binding site at the 5' enhancer region
173. Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells
174. Reduced numatrin/B23/nucleophosmin labeling in apoptotic Jurkat T-lymphoblasts
175. A constitutive nucleolar protein identified as a member of the nucleoplasmin family
176. Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site
177. The t(2;5) in human lymphomas
178. Characterization of t(2;5) reciprocal transcripts and genomic breakpoints in CD30+ cutaneous lymphoproliferations
179. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis
180. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity
181. Nucleolar localization of the nucleophosmin anaplastic lymphoma kinase is not required for malignant transformation
182. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene upregulation in rat 1a fibroblasts
183. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice
184. Role of STAT5 in NPM/ALK-mediated malignant transformation of lymphoid cells
185. Role of PI-3K-AKT pathway in NPM/ALK-mediated malignant transformation of lymphoid cells
186. The tyrosine kinase NPM-ALK, associated with anaplastic large cell lymphoma, binds the intra-cellular domain of the surface receptor CD30 but is not activated by CD30 activation
187. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs
188. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
189. The human purH gene product, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. Cloning, sequencing, expression, purification, kinetic analysis, and domain mapping
190. Characterization of molecularly cloned human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase
191. Structure and functional relationships in human pur H
192. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain
193. Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRF-T3 oncogene
194. Characterization and chromosomal mapping of the human TFG gene involved in thyroid carcinoma
195. Tropomyosin isoforms in nonmuscle cells
196. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences
197. Tissue-specific expression of the human tropomyosin gene involved in the generation of the trk oncogene
198. A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas
199. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma
200. cDNA cloning, expression pattern, and chromosomal localization of Mlf1, murine homologue of a gene involved in myelodysplasia and acute leukemia
201. MNDA binds NPM/B23 and the NPM-MLF1 chimera generated by the t(3;5) associated with myelodysplastic syndrome and acute myeloid leukemia
202. Apoptosis induced by the myelodysplastic syndrome-associated NPM-MLF1 chimeric protein
203. HLS7, a hematopoietic lineage switch gene homologous to the leukemia-inducing gene MLF1
204. NPM-MLF1 fusion protein downregulates p27kIP1 through the novel Jab1-mediated pathway
205. cDNA cloning, tissue distribution, and chromosomal localization of myelodysplasia/myeloid leukemia factor 2 (MLF2)
206. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARα and NPM-RARaα
207. NPM-RARα transgenic mice develop APL-like leukemia
208. The impact of differential binding of wild-type RARα, PML-PLZF- and NPM-RARα fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia
209. The t(5;17) acute promyelocytic leukemia fusion protein NPM-RAR interacts with co-repressor and co-activator proteins and exhibits both positive and negative transcriptional properties
210. Guidelines for Cancer Cytogenetics
211. Detection of the t(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's lymphoma by two-color fluorescence in situ hybridization
212. Construction of a YAC contig and a STS map spanning at least seven megabase pairs in chromosome 5q34-35
213. Translocation t(2;5) is not a primary event in Hodgkin's disease. Simultaneous immunophenotyping and interphase cytogenetics
214. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas
215. Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma
216. Detection of the NPM-ALK genomic rearrangement of Ki-1 lymphoma and isolation of the involved NPM and ALK introns
217. Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma; but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphoid papulosis
218. Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease
219. Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis
220. Detection of normal and chimeric nucleophosmin in human cells
221. Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma
222. The clinicopathological features of anaplastic large cell lymphomas expressing p80(NPM/ALK)
223. + primary cutaneous lymphoproliferative disorders and Hodgkin's disease
224. Practical role of molecular diagnostics in non-Hodgkin's lymphomas
225. Chromosomal abnormalities in nodal and extranodal CD30+ anaplastic large cell lymphomas: Infrequent detection of the t(2;5) in extranodal lymphomas
226. The use of fluorescent in situ hybridization for detection of the t(2;5)(p23;q35) translocation in anaplastic large-cell lymphoma
227. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood
228. Pattern of expression of NPM/ALK fusion transcripts in pediatric lymphomas
229. NPM/ALK rearrangements in indolent cutaneous lesions
230. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders
231. Serum levels of the sCD30 molecules in anaplastic large cell lymphoma (ALCL): Relationship with the expression of ALK p80 protein
232. NPM/ALK gene fusion transcripts identify a distinct subgroup of null Ki-1 positive anaplastic large cell lymphomas
233. The presence of transcripts of the fusion of kinase gene ALK to nucleophosmin gene NPM in the t(2;5)(p23;q35) translocation defines subsets of non-Hodgkin's lymphoma with or without CD30 (Ki-1) expression and Hodgkin's disease
234. Detection of the t(2;5)(p23;q35) chromosomal translocation in large B-cell lymphomas other than anaplastic large cell lymphoma
235. Nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) fusion transcript in malignant lymphoma
236. NPM/ALK fusion mRNA expression in Hodgkin and Reed-Sternberg cells is rare but does occur: Results from single-cell cDNA analysis
237. NPM-ALK gene fusion and Hodgkin's disease
238. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease
239. Large-cell anaplastic lymphoma-specific translocation in Hodgkin's disease - Author's reply
240. Absence of the t(2;5) in Hodgkin's disease
241. Differences in clinical behavior and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma or T-cell or null phenotype
242. Successful treatment strategy for Ki-1 anaplastic patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies
243. CD30/Ki-1-positive lymphoproliferative disorders of the skin - clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Lymphoma Project Group
244. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: A clinicopathologic study of 65 cases
245. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis
246. The pathogenesis of large cell transformation in cutaneous T-cell lymphoma is not associated with t(2;5)(p23;q35) chromosomal translocation
247. CD30-positive anaplastic large cell lymphoma cell lines
248. False human hematopoietic cell lines: Cross-contaminations and misinterpretations
249. t(2;5) and failure-free survival (FFS) of doxorubicin-treated anaplastic large cell lymphoma (ALCL)
250. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large cell lymphoma
251. Ribozyme-mediated cleavage of the NPM-ALK transcript coding for a chimeric tyrosine kinase associated with anaplastic large cell lymphoma
252. Presence of the t(2;5) in Hodgkin's disease - response
253. Presence of t(2;5) in primary CD30+ cutaneous lympho-proliferative disorders - Response
254. AML1/ETO is transcribed in the cord blood and bone marrow of healthy individuals
255. Expression of bcl-2 and bcl-2-lg fusion transcripts in normal and neoplastic cells
256. Bcl2 translocation frequency rises with age in humans
257. Bcl-2/Jh rearrangements in benign lymphoid tissus with follicular hyperplasia
258. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals
259. Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers
260. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
261. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
262. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation
263. No evidence for MLL/AF4 expression in normal cord blood samples
264. Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: Distinct origin of normal versus leukemia ALL1 fusion transcripts
265. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors
266. Detection of the NPM/ALK fusion transcript in reactive lymphoid tissue
267. Detection of the t(2;5)-associated NPM/ALK fusion cDNA in peripheral blood cells of healthy individuals
268. The t(2;5)(p23;q35) is not detectable in normal donor peripheral blood mononuclear cells by polymerase chain reaction amplification (PCR) of genomic DNA
269. What significance should we attribute to the detection of MLL fusion transcripts
270. The bcl-2 gene, follicular lymphoma, and Hodgkin's disease
271. Role of the Bcl-2 oncogene in Hodgkin's disease
272. The t(14;18) translocation in Hodgkin's disease
273. Gene analysis and Epstein-Barr viral genome studies of Hodgkin's disease
274. Molecular biologic studies of Hodgkin's disease
275. Lymphocyte predominance Hodgkin's disease (nodular paragranuloma) - A bcl-2 negative germinal centre lymphoma
276. The bcl-2 gene translocation is undetectable in Hodgkin's disease by Southern blot hybridization and polymerase chain reaction
277. Bcl-2 rearrangement in Hodgkin's disease and reactive lymph nodes
278. Direct sequence analysis of the t(14;18) chromosomal translocation in Hodgkin's disease
279. The t(14;18) chromosomal translocation and bcl-2 protein expression in Hodgkin's disease
280. Low incidence of mbr bcl-2/JH fusion genes in Hodgkin's disease
281. Bcl-2 in Hodgkin's disease: A correlative study of t(14;18) and bcl-2 protein expression
282. Expression of the bcl-2 oncogene product and chromosomal translocation t(14;18) in Hodgkin's disease
283. Absence of t(14;18) major and minor breakpoints and of bcl-2 protein overproduction in Reed-Sternberg cells of Hodgkin's disease
284. Detection of t(14;18) in Hodgkin's disease by the polymerase chain reaction: Correlation with EBV genome and histologic subtype
285. Rearrangement of bcl-2 is detectable in Hodgkin's disease by polymerase chain reaction
286. Nachweis des bcl-2/JH-Genrearrangements in Non-Hodgkin-Lymphomen and chronischer Tonsillitis, nicht aber in Hodgkin-Lymphomen
287. The bcl-2/JH gene rearrangement is undetectable in Hodgkin's lymphomas: Results from the German Hodgkin trial
288. Chromosomal abnormalities in patients with Hodgkin's disease: Evidence for frequent involvement of the 14q chromosomal region but infrequent bcl-2 gene rearrangement in Reed-Sternberg cells
289. bcl-2 rearrangement in Hodgkin's disease. Results of polymerase chain reaction, flow cytometry, and sequencing on formalin-fixed, paraffin-embedded tissue
290. Absence of bcl-2 major breakpoint region and JH gene rearrangement on lymphocyte predominance Hodgkin's disease
291. Detection of specific t(14;18) chromosomal translocations in fixed tissues
292. Involvement of the bcl-2 gene in Hodgkin's disease
293. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas
294. Absence of bcl-2 translocation in Hodgkin's disease: Analysis by polymerase chain reaction
295. Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients
296. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation
297. Chromosomal abnormalities in Hodgkin's disease
298. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation